Clinical Trials
1
0 active
Approvals
123
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Recruiting
1
100.0%
- The U.S. Economic Development Administration has awarded $15.97 million to launch the End-to-End Commercialization Project led by Civica, Inc., with support from Phlow Corp. and Occam Systems. - The project will establish an integrated domestic pathway from key starting materials through API manufacturing, finished dose formulation, FDA approval, and commercial delivery to patients. - Four essential sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—will be the initial focus, targeting emergency, anesthesia, and critical care settings. - The initiative builds on over $1.7 billion in prior investments and involves more than 55 Alliance for Building Better Medicine partners spanning industry, academia, government, and workforce development.
- CivicaScript has launched insulin glargine-yfgn, an interchangeable biosimilar to Lantus, priced at $45 per box of five pens to pharmacies with a maximum consumer price of $55. - The nonprofit also introduced ustekinumab-aauz, a biosimilar to Stelara for inflammatory conditions, with 12-week supplies priced at $985 for 90mg and $575 for 45mg. - Both products represent significant cost reductions compared to current market prices and are part of CivicaScript's transparent pricing model to improve medication affordability. - The insulin launch results from a manufacturing partnership with Biocon Biologics and will be distributed nationally under CivicaScript's label, with CalRx branding in California pharmacies.
- California becomes the first state to sell its own brand of generic insulin through the CalRx program, with five-pack insulin pens available for $55 starting January 1, 2025. - The state-branded insulin represents a significant cost reduction compared to current market prices, where similar products from name brand companies cost pharmacies between $89 and $411. - Governor Newsom's initiative bypasses traditional pharmaceutical companies through a $50 million contract with nonprofit manufacturer Civica Rx, marking a milestone in state-led healthcare cost reduction efforts. - The program launches alongside new legislation capping insulin co-pays at $35 in California, addressing concerns that insulin users without insurance can pay up to $400 for small vials.
- Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County. - The AstraZeneca project represents part of a $50 billion five-year investment plan and will be the company's largest global manufacturing investment, strategically located near the University of Virginia's Manning Institute of Biotechnology. - Both pharmaceutical giants are expanding domestic manufacturing capacity amid potential tariff threats, with Eli Lilly committing $50 billion over five years to double its U.S. manufacturing investments. - The Virginia facilities will strengthen a pharmaceutical manufacturing corridor extending from the Shenandoah Valley to Richmond, positioning the state as a major center for advanced pharmaceutical production.
- CivicaScript, a nonprofit company, has launched generic dimethyl fumarate delayed-release capsules for multiple sclerosis treatment at $47 per bottle to pharmacies, with a maximum retail price of $68. - The new pricing offers average savings of $4,300 per month compared to other generic versions, potentially reducing significant out-of-pocket costs for patients during insurance deductible phases. - This launch represents CivicaScript's second generic medication release in three months, following their successful abiraterone launch that saved consumers 64% and payers 92%. - The medication is indicated for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
• California's ambitious $100-million CalRx insulin initiative, announced two years ago with a promised 2024 delivery, is significantly behind schedule with potential delays extending to 2030. • Civica, Inc., the contracted manufacturer, has not yet begun clinical trials or FDA approval process for the five planned insulin types, though manufacturing has commenced. • The delay impacts over 3.5 million Californians with diabetes, while alternative solutions like insulin price caps have been vetoed by Governor Newsom in favor of the CalRx program.
